ITGAX and melanoma: Moreover, CD163+/CD11c+ DCs within CRATERs presented a statistically significant increase in HLA-A and HLA-DPB1 levels, corresponding to MHC class II, and MART-1 melanoma antigen, compared with elsewhere in the tumor (Figures 6C and 6D).